Blue Arbor Technologies recently secured a powerful strategic partner. Ottobock led a $5M Series A investment round. This funding accelerates Blue Arbor’s prosthetic control solutions. Specifically, it supports the RESTORE™ Neuromuscular Interface System. This platform connects prostheses directly to residual muscles. Consequently, it creates more natural movement for patients.
“Blue Arbor’s neuromuscular interface represents a highly promising innovation for the next technological leap in prosthetic control, one that aligns perfectly with our mission to enhance human mobility through meaningful innovation,” said Oliver Jakobi, Chief Executive Officer of Ottobock. “We were impressed by their first-in-human case at the Medical University of Vienna and are excited to partner with them as they move into clinical trials.”
The RESTORE system uses wireless sensors. Therefore, patients can control fingers and wrists simultaneously. Early trials show stable signals for over five years. This performance addresses a major limitation in current medical technology.
“The RESTORE System is about restoring intuitive, volitional movement, not asking patients to adapt to technology, but designing technology that adapts to human biology,” said Tod Borton, Chief Executive Officer of Blue Arbor Technologies. “Ottobock’s investment and strategic partnership validate the transformative potential of this platform and position us to move faster toward broad clinical impact.”
Breakthrough in Bionic Mobility
Furthermore, clinical momentum is growing quickly. Surgeons in Vienna recently completed the first human implant. The patient demonstrated functional use within just a few days. Similarly, the system feels more responsive than existing tools.
“What makes this technology remarkable is how quickly patients can translate intent into movement,” said Dr. Oskar Aszmann, Director of the Christian Doppler Laboratory for Restoration of Extremity Function at the Medical University of Vienna. “We are seeing control that feels more natural and responsive than anything currently available, which has profound implications for patient independence and quality of life.”
Blue Arbor’s approach is built on deep leadership at the intersection of neuromuscular science, reconstructive surgery, and neural engineering. Over the past 17 years, the company’s three founders, Dr. Paul Cederna, President; Dr. Theodore Kung, Chief Medical Officer; and Dr. Alex Vaskov, Chief Technology Officer, have collectively been awarded more than $60 million in direct research grant funding, driving the foundational science behind the RESTORE™ System. Their groundbreaking work has resulted in more than 200 peer-reviewed publications.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
